Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has shared an announcement.
NeuroScientific Biopharmaceuticals reported a strong March quarter as it advanced its StemSmart™ cell therapy program for fistulising Crohn’s disease. The company is targeting difficult-to-treat inflammatory indications and is positioning itself for larger clinical studies and eventual commercialisation, supported by specialist manufacturing partners and a solid cash position.
Interim results from the Special Access Scheme showed three of four Crohn’s patients achieved a clinical response to StemSmart™, with the fourth showing partial improvement, reinforcing prior trial data in refractory disease. In parallel, NeuroScientific initiated technology transfer of StemSmart™ manufacturing to Q-Gen Cell Therapeutics to enable scalable GMP production for Phase 2 trials, while progressing regulatory planning and site engagement in Australia and the U.S., backed by $5.68 million in cash to fund ongoing development.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd. is an Australian biotechnology company focused on developing novel technologies for immune-mediated inflammatory diseases. Its lead asset, StemSmart™, is a mesenchymal stem cell therapeutic platform being advanced for severe, treatment-resistant conditions such as fistulising Crohn’s disease, with plans to scale manufacturing for later-stage clinical development.
Average Trading Volume: 279,552
Technical Sentiment Signal: Sell
Current Market Cap: A$38.25M
See more insights into NSB stock on TipRanks’ Stock Analysis page.